Fibrillary Glomerulonephritis and Multiple Myeloma: A Case Report and Literature Review.

IF 0.7 Q4 ONCOLOGY
Case Reports in Oncology Pub Date : 2025-04-04 eCollection Date: 2025-01-01 DOI:10.1159/000545498
Taiki Ishida, Ken Morita, Yosuke Masamoto, Hideaki Mizuno, Kazuki Taoka, Hiroyuki Abe, Motoki Odawara, Yosuke Hirakawa, Masaomi Nangaku, Mineo Kurokawa
{"title":"Fibrillary Glomerulonephritis and Multiple Myeloma: A Case Report and Literature Review.","authors":"Taiki Ishida, Ken Morita, Yosuke Masamoto, Hideaki Mizuno, Kazuki Taoka, Hiroyuki Abe, Motoki Odawara, Yosuke Hirakawa, Masaomi Nangaku, Mineo Kurokawa","doi":"10.1159/000545498","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Fibrillary glomerulonephritis (FGN) is a rare form of immune complex-mediated primary glomerular disease frequently coexisting with malignancies or autoimmune diseases. The kidney prognosis is extremely poor, with approximately 50% of patients progressing to end-stage kidney disease within 2-4 years after diagnosis. However, no established treatment currently exists.</p><p><strong>Case presentation: </strong>Here we describe a rare case of FGN diagnosed in a patient progressing from monoclonal gammopathy to multiple myeloma. The histopathological findings of the kidney biopsy were consistent with classical FGN and revealed no evidence of myeloma cast nephropathy. Albumin-dominant, Bence Jones protein-negative proteinuria further supported this diagnosis. The patient was successfully treated with anti-myeloma chemotherapies including autologous stem cell transplant, resulting in significant improvement in kidney function.</p><p><strong>Conclusion: </strong>Based on our experience, secondary FGN associated with plasma cell neoplasms may represent a rare entity that responds favorably to anti-myeloma therapies. Initial investigations to rule out coexistent plasma cell neoplasms are crucial for the optimal management of FGN patients.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"554-562"},"PeriodicalIF":0.7000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058109/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000545498","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Fibrillary glomerulonephritis (FGN) is a rare form of immune complex-mediated primary glomerular disease frequently coexisting with malignancies or autoimmune diseases. The kidney prognosis is extremely poor, with approximately 50% of patients progressing to end-stage kidney disease within 2-4 years after diagnosis. However, no established treatment currently exists.

Case presentation: Here we describe a rare case of FGN diagnosed in a patient progressing from monoclonal gammopathy to multiple myeloma. The histopathological findings of the kidney biopsy were consistent with classical FGN and revealed no evidence of myeloma cast nephropathy. Albumin-dominant, Bence Jones protein-negative proteinuria further supported this diagnosis. The patient was successfully treated with anti-myeloma chemotherapies including autologous stem cell transplant, resulting in significant improvement in kidney function.

Conclusion: Based on our experience, secondary FGN associated with plasma cell neoplasms may represent a rare entity that responds favorably to anti-myeloma therapies. Initial investigations to rule out coexistent plasma cell neoplasms are crucial for the optimal management of FGN patients.

原纤维性肾小球肾炎合并多发性骨髓瘤1例报告及文献复习。
简介:原纤维性肾小球肾炎(FGN)是一种罕见的免疫复合物介导的原发性肾小球疾病,常与恶性肿瘤或自身免疫性疾病共存。肾脏预后极差,约50%的患者在诊断后2-4年内进展为终末期肾脏疾病。然而,目前尚无确定的治疗方法。病例介绍:在这里我们描述了一个罕见的病例FGN诊断的患者进展从单克隆伽玛病多发性骨髓瘤。肾活检的组织病理学结果与典型的FGN一致,没有发现骨髓瘤铸造肾病的证据。白蛋白显性、Bence Jones蛋白阴性蛋白尿进一步支持了这一诊断。患者成功地接受了包括自体干细胞移植在内的抗骨髓瘤化疗,导致肾功能显著改善。结论:根据我们的经验,与浆细胞肿瘤相关的继发性FGN可能是一种罕见的实体,对抗骨髓瘤治疗反应良好。排除共存浆细胞肿瘤的初步调查对FGN患者的最佳治疗至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
151
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信